ATE319996T1 - Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin - Google Patents

Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin

Info

Publication number
ATE319996T1
ATE319996T1 AT00981763T AT00981763T ATE319996T1 AT E319996 T1 ATE319996 T1 AT E319996T1 AT 00981763 T AT00981763 T AT 00981763T AT 00981763 T AT00981763 T AT 00981763T AT E319996 T1 ATE319996 T1 AT E319996T1
Authority
AT
Austria
Prior art keywords
mortalin
cure
finding
cancer
interaction domain
Prior art date
Application number
AT00981763T
Other languages
English (en)
Inventor
Renu Chugai Wadhwa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE319996T1 publication Critical patent/ATE319996T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00981763T 1999-12-16 2000-12-15 Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin ATE319996T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35754599 1999-12-16

Publications (1)

Publication Number Publication Date
ATE319996T1 true ATE319996T1 (de) 2006-03-15

Family

ID=18454687

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00981763T ATE319996T1 (de) 1999-12-16 2000-12-15 Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin

Country Status (6)

Country Link
US (1) US20030087263A1 (de)
EP (1) EP1243923B1 (de)
AT (1) ATE319996T1 (de)
AU (1) AU1891801A (de)
DE (1) DE60026576T2 (de)
WO (1) WO2001044807A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1601969A2 (de) 2003-03-08 2005-12-07 Auvation Ltd Marker für dickdarmkrebs
EP1536230A1 (de) * 2003-11-28 2005-06-01 Deutsches Rheuma-Forschungszentrum Berlin Durchflusszytometrischer Partikel-basierter Bindungsassay
JP2006089471A (ja) * 2004-08-26 2006-04-06 National Institute Of Advanced Industrial & Technology 癌の治療における抗モータリン２抗体と機能性核酸の使用
EP2118123B1 (de) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilisierte p53-peptide und deren verwendungen
EP2508531B1 (de) 2007-03-28 2016-10-19 President and Fellows of Harvard College Geheftete Polypeptide
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
MX358886B (es) 2011-10-18 2018-08-31 Aileron Therapeutics Inc Macrociclos peptidomimeticos.
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
CN107216380A (zh) 2012-02-15 2017-09-29 爱勒让治疗公司 拟肽大环化合物
EP2906954B1 (de) * 2012-10-09 2018-04-11 Ramot at Tel-Aviv University Ltd. Verfahren und kits zur prognose von krebs unter verwendung von löslichem mortalin im blut
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
CN112972378A (zh) 2014-09-24 2021-06-18 艾瑞朗医疗公司 拟肽大环化合物及其制剂
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023555A1 (en) * 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Method of prolonging normal cell life span
US20020009743A1 (en) * 2000-05-17 2002-01-24 Carpenter Melissa K. Neural progenitor cell populations
JP2001354564A (ja) * 2000-06-14 2001-12-25 Chugai Bunshi Igaku Kenkyusho:Kk カチオン性ローダシアニン系色素誘導体を有効成分とする、ｍｏｔ−２蛋白質とｐ５３蛋白質の相互作用阻害剤

Also Published As

Publication number Publication date
US20030087263A1 (en) 2003-05-08
AU1891801A (en) 2001-06-25
EP1243923A4 (de) 2004-05-06
DE60026576T2 (de) 2007-01-18
WO2001044807A1 (en) 2001-06-21
EP1243923A1 (de) 2002-09-25
EP1243923B1 (de) 2006-03-08
DE60026576D1 (de) 2006-05-04

Similar Documents

Publication Publication Date Title
ATE319996T1 (de) Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin
EP2267018A3 (de) Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
WO2002032925A3 (en) Protein scaffolds for antibody mimics and other binding proteins
CY1110549T1 (el) Ικριωματα πρωτεϊνων για μιμητικα αντισωματων και αλλες πρωτεϊνες συνδεσης
ATE555202T1 (de) Verfahren zur lieferung von rna-interferenz und verwendungen damit
ATE540319T1 (de) Verfahren für die bestimmung von fk506
WO2005111066A3 (en) Polypeptides from non-typeable haemophilus influenzae
WO2020198264A8 (en) Modified cleavases, uses thereof and related kits
DE60133982D1 (de) Biosensor und verfahren zum analysieren von blutkomponenten
ATE420366T1 (de) ERWEITERTER ßTETHERINGß ANSATZ ZUM SCHNELLEN AUFFINDEN VON LIGANDEN
WO2003011898A3 (fr) Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
ATE554106T1 (de) Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
DE60318744D1 (de) ZUSAMMENSETZUNG AUF BASIS VON 2-CYANOACRYLAT, VERFAHREN UND MITTEL ZUR EVALUIERUNG DER HuRTUNG DAVON
ATE366420T1 (de) Kit und verfahren zur bestimmung von protein esm- 1
DK2090582T3 (da) Bindende molekyler til human faktor VIII- og faktor VIII-lignende proteiner
DE602004030041D1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
DE60206173D1 (de) Härtende zusammensetzung und verfahren zum aufbringen von alkydbeschichtungsmaterial damit
WO2003002724A3 (en) Proteins, druggable regions of proteins and target analysis for chemistry of therapeutics
DE602004032345D1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
DE60213900D1 (de) Bolzen und diesen verwendendes Verfahren zum Spannen von Bauteilen
DE69924120D1 (de) Für ataxin-2-bindende proteine kodierende nukleinsäure, damit verwandten produkten und verfahren zur deren anwendung
ATE284034T1 (de) Verfahren zum nachweis von protein s
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
DE59702207D1 (de) Verfahren zur eignungsprüfung von faktor viii-haltigen proteinfraktionen
ATE332916T1 (de) Farbstoff-markiertes peptid und dessen verwendung zur diagnostik

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties